Angiosarcoma

The Lancet Oncology

Volumn 11, Issue 10, 2010, Pages 983-991

  Young, Robin J ^a   Brown, Nicola J ^a   Reed, Malcolm W ^a   Hughes, David ^b   Woll, Penella J ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; ALPHA INTERFERON; ANTHRACYCLINE DERIVATIVE; AXITINIB; BEVACIZUMAB; COMBRETASTATIN; DOCETAXEL; DOXORUBICIN; GEMCITABINE; IFOSFAMIDE; INTERFERON; INTERLEUKIN 2; PACLITAXEL; SORAFENIB; SUNITINIB; TAXANE DERIVATIVE; THALIDOMIDE;

ADVANCED CANCER; ANGIOSARCOMA; ANTIANGIOGENIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER CONTROL; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CHROMOSOME ABERRATION; CHRONIC DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; DRUG TARGETING; ELDERLY CARE; ENDOTHELIUM CELL; HEAD; HISTOPATHOLOGY; HUMAN; LYMPHEDEMA; METASTASIS; MOLECULAR BIOLOGY; MOLECULARLY TARGETED THERAPY; NECK; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCUPATIONAL EXPOSURE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RADIATION EXPOSURE; REVIEW; RISK FACTOR; SCALP; SKIN DISEASE; SOFT TISSUE SARCOMA; THROMBOCYTOPENIA; FEMALE; GENETICS; HEMANGIOSARCOMA; MALE; PATHOLOGY; PREDICTIVE VALUE; TREATMENT OUTCOME;

DIAGNOSIS, DIFFERENTIAL; FEMALE; HEMANGIOSARCOMA; HUMANS; MALE; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; RISK FACTORS; TREATMENT OUTCOME;

EID: 77957331576     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(10)70023-1     Document Type: Review

References (79)

1. Weiss SW, Goldblum JR Enzinger & Weiss's soft tissue tumors 2008, Mosby. 5th edn.
2. Schlemmer M, Reichardt P, Verweij J, et al. Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group. Eur J Cancer 2008, 44:2433-2436.
3. Fury MG, Antonescu CR, Van Zee KJ, Brennan MF, Maki RG A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J 2005, 11:241-247.
4. Coindre JM, Terrier P, Guillou L, et al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer 2001, 91:1914-1926.
5. Rouhani P, Fletcher CD, Devesa SS, Toro JR Cutaneous soft tissue sarcoma incidence patterns in the U.S.: an analysis of 12,114 cases. Cancer 2008, 113:616-627.
6. Mark RJ, Poen JC, Tran LM, Fu YS, Juillard GF Angiosarcoma. A report of 67 patients and a review of the literature. Cancer 1996, 77:2400-2406.
7. Abraham JA, Hornicek FJ, Kaufman AM, et al. Treatment and outcome of 82 patients with angiosarcoma. Ann Surg Oncol 2007, 14:1953-1967.
8. Naka N, Ohsawa M, Tomita Y, Kanno H, Uchida A, Aozasa K Angiosarcoma in Japan: a review of 99 cases. Cancer 1995, 75:989-996.
9. Fayette J, Martin E, Piperno-Neumann S, et al. Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases. Ann Oncol 2007, 18:2030-2036.
10. Rossi S, Fletcher CD Angiosarcoma arising in hemangioma/vascular malformation: report of four cases and review of the literature. Am J Surg Pathol 2002 Oct, 26:1319-1329.
11. Stewart FW, Treves N Lymphangiosarcoma in postmastectomy lymphedema; a report of six cases in elephantiasis chirurgica. Cancer 1948, 1:64-81.
12. Huang J, Mackillop WJ Increased risk of soft tissue sarcoma after radiotherapy in women with breast carcinoma. Cancer 2001, 92:172-180.
13. Virtanen A, Pukkala E, Auvinen A Angiosarcoma after radiotherapy: a cohort study of 332,163 Finnish cancer patients. Br J Cancer 2007, 97:115-117.
14. Karlsson P, Holmberg E, Samuelsson A, Johansson KA, Wallgren A Soft tissue sarcoma after treatment for breast cancer-a Swedish population-based study. Eur J Cancer 1998, 34:2068-2075.
15. West JG, Weitzel JN, Tao ML, Carpenter M, West JE, Fanning C BRCA mutations and the risk of angiosarcoma after breast cancer treatment. Clin Breast Cancer 2008, 8:533-537.
16. Bosetti C, La Vecchia C, Lipworth L, McLaughlin JK Occupational exposure to vinyl chloride and cancer risk: a review of the epidemiologic literature. Eur J Cancer Prev 2003, 12:427-430.
17. Ron E Cancer risks from medical radiation. Health Phys 2003, 85:47-59.
18. Locker GY, Doroshow JH, Zwelling LA, Chabner BA The clinical features of hepatic angiosarcoma: a report of four cases and a review of the English literature. Medicine (Baltimore) 1979, 58:48-64.
19. Ben-Izhak O, Kerner H, Brenner B, Lichtig C Angiosarcoma of the colon developing in a capsule of a foreign body. Report of a case with associated hemorrhagic diathesis. Am J Clin Pathol 1992, 97:416-420.
20. Weiss WM, Riles TS, Gouge TH, Mizrachi HH Angiosarcoma at the site of a Dacron vascular prosthesis: a case report and literature review. J Vasc Surg 1991, 14:87-91.
21. McDonald DJ, Enneking WF, Sundaram M Metal-associated angiosarcoma of bone: report of two cases and review of the literature. Clin Orthop Relat Res 2002, 369:206-214.
22. Folpe AL, Johnston CA, Weiss SW Cutaneous angiosarcoma arising in a gouty tophus: report of a unique case and a review of foreign material-associated angiosarcomas. Am J Dermatopathol 2000, 22:418-421.
23. Ahmed I, Hamacher KL Angiosarcoma in a chronically immunosuppressed renal transplant recipient: report of a case and review of the literature. Am J Dermatopathol 2002, 24:330-335.
24. Goedert JJ, Cote TR, Virgo P, et al. Spectrum of AIDS-associated malignant disorders. Lancet 1998, 351:1833-1839.
25. Schmid H, Zietz C Human herpesvirus 8 and angiosarcoma: analysis of 40 cases and review of the literature. Pathology 2005, 37:284-287.
26. Pawlik TM, Paulino AF, McGinn CJ, et al. Cutaneous angiosarcoma of the scalp: a multidisciplinary approach. Cancer 2003, 98:1716-1726.
27. Lahat G, Dhuka AR, Lahat S, et al. Outcome of locally recurrent and metastatic angiosarcoma. Ann Surg Oncol 2009, 16:2502-2559.
28. Calonje E, Fletcher CDM Vascular Tumors. Diagnostic Histopathology of Tumors 2007, 41-76. Churchill Livingstone. 3rd edn. C.D.M. Fletcher (Ed.).
29. Weiss SW, Lasota J, Miettinen MM Angiosarcoma of soft tissue. WHO classification tumours of soft tissue and bone 2002, 175-177. IARC Press. C.D.M. Fletcher, K.K. Unni, F. Mertens (Eds.).
30. Ohsawa M, Naka N, Tomita Y, Kawamori D, Kanno H, Aozasa K Use of immunohistochemical procedures in diagnosing angiosarcoma. Evaluation of 98 cases. Cancer 1995, 75:2867-2874.
31. Itakura E, Yamamoto H, Oda Y, Tsuneyoshi M Detection and characterization of vascular endothelial growth factors and their receptors in a series of angiosarcomas. J Surg Oncol 2008, 97:74-81.
32. Zietz C, Rossle M, Haas C, et al. MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas. Am J Pathol 1998, 153:1425-1433.
33. Dim D, Ravi V, Tan J, Hicks D, Wong M The actin-bundling motility protein fascin and vascular endothelial growth factor (VEGF) are universally over-expressed in human angiosarcoma. Proc Am Soc Clin Oncol 2007, 25:10068.
34. Naka N, Tomita Y, Nakanishi H, et al. Mutations of p53 tumor-suppressor gene in angiosarcoma. Int J Cancer 1997, 71:952-955.
35. Ueda T, Oji Y, Naka N, et al. Overexpression of the Wilms' tumor gene WT1 in human bone and soft-tissue sarcomas. Cancer Sci 2003, 94:271-276.
36. Johnson KD, Glinskii OV, Mossine VV, et al. Galectin-3 as a potential therapeutic target in tumors arising from malignant endothelia. Neoplasia 2007, 9:662-670.
37. Arbiser JL, Moses MA, Fernandez CA, et al. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc Natl Acad Sci USA 1997, 94:861-866.
38. Przygodzki RM, Finkelstein SD, Keohavong P, et al. Sporadic and Thorotrast-induced angiosarcomas of the liver manifest frequent and multiple point mutations in K-ras-2. Lab Invest 1997, 76:153-159.
39. Weihrauch M, Bader M, Lehnert G, et al. Mutation analysis of K-ras-2 in liver angiosarcoma and adjacent nonneoplastic liver tissue from patients occupationally exposed to vinyl chloride. Environ Mol Mutagen 2002, 40:36-40.
40. Garcia JM, Gonzalez R, Silva JM, et al. Mutational status of K-ras and TP53 genes in primary sarcomas of the heart. Br J Cancer 2000, 82:1183-1185.
41. LaMontagne KR, Moses MA, Wiederschain D, et al. Inhibition of MAP kinase kinase causes morphological reversion and dissociation between soft agar growth and in vivo tumorigenesis in angiosarcoma cells. Am J Pathol 2000, 157:1937-1945.
42. Perry B, Banyard J, McLaughlin ER, et al. AKT1 overexpression in endothelial cells leads to the development of cutaneous vascular malformations in vivo. Arch Dermatol 2007, 143:504-506.
43. Naito S, Shimizu K, Nakashima M, et al. Overexpression of Ets-1 transcription factor in angiosarcoma of the skin. Pathol Res Pract 2000, 196:103-109.
44. Dictor M, Bendsoe N, Runke S, Witte M Major basement membrane components in Kaposi's sarcoma, angiosarcoma and benign vascular neogenesis. J Cutan Pathol 1995, 22:435-441.
45. Yamamoto T, Umeda T, Nishioka K Immunohistological distribution of stem cell factor and kit receptor in angiosarcoma. Acta Derm Venereol 2000, 80:443-445.
46. Miettinen M, Sarlomo-Rikala M, Lasota J KIT expression in angiosarcomas and fetal endothelial cells: lack of mutations of exon 11 and exon 17 of C-kit. Mod Pathol 2000, 13:536-541.
47. Hornick JL, Fletcher CD Immunohistochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution. Am J Clin Pathol 2002, 117:188-193.
48. Komdeur R, Hoekstra HJ, Molenaar WM, et al. Clinicopathologic assessment of postradiation sarcomas: KIT as a potential treatment target. Clin Cancer Res 2003, 9:2926-2932.
49. DuBois S, Demetri G Markers of angiogenesis and clinical features in patients with sarcoma. Cancer 2007, 109:813-819.
50. Wong KF, So CC, Wong N, Siu LL, Kwong YL, Chan JK Sinonasal angiosarcoma with marrow involvement at presentation mimicking malignant lymphoma: cytogenetic analysis using multiple techniques. Cancer Genet Cytogenet 2001, 129:64-68.
51. Sobin LH, Wittekind CH TNM classification of malignant tumours, 6th edn (UICC) 2002, Wiley-Liss, New York.
52. Mocellin S, Rossi CR, Brandes A, Nitti D Adult soft tissue sarcomas: conventional therapies and molecularly targeted approaches. Cancer Treat Rev 2006, 32:9-27.
53. Sher T, Hennessy BT, Valero V, et al. Primary angiosarcomas of the breast. Cancer 2007, 110:173-178.
54. Naka N, Ohsawa M, Tomita Y, et al. Prognostic factors in angiosarcoma: a multivariate analysis of 55 cases. J Surg Oncol 1996, 61:170-176.
55. Vorburger SA, Xing Y, Hunt KK, et al. Angiosarcoma of the breast. Cancer 2005, 104:2682-2688.
56. Maeda T, Tateishi U, Hasegawa T, Ojima H, Arai Y, Sugimura K Primary hepatic angiosarcoma on coregistered FDG PET and CT images. AJR Am J Roentgenol 2007, 188:1615-1617.
57. Woll PJ, van Glabbeke M, Hohenberger P, et al. Adjuvant chemotherapy (CT) with doxorubicin and ifosfamide in resected soft tissue sarcoma (STS): Interim analysis of a randomised phase III trial. Proc Am Soc Clin Oncol 2007, 25. abstr 10008.
58. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet 1997, 350:1647-1654.
59. DeMartelaere SL, Roberts D, Burgess MA, et al. Neoadjuvant chemotherapy-specific and overall treatment outcomes in patients with cutaneous angiosarcoma of the face with periorbital involvement. Head Neck 2008, 30:639-646.
60. Van Glabbeke M, van Oosterom AT, Oosterhuis JW, et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens-a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 1999, 17:150-157.
61. Budd GT Management of angiosarcoma. Curr Oncol Rep 2002, 4:515-519.
62. Asmane I, Litique V, Heymann S, et al. Adriamycin, cisplatin, ifosfamide and paclitaxel combination as front-line chemotherapy for locally advanced and metastatic angiosarcoma. Analysis of three case reports and review of the literature. Anticancer Res 2008, 28:3041-3045.
63. Anderson SE, Keohan ML, D'Adamo DR, Maki RG A retrospective analysis of vinorelbine chemotherapy for patients with previously treated soft-tissue sarcomas. Sarcoma 2006, 2006:15947.
64. Gautam U, Hurley J, Silva OE, Benedetto PW, Robles C Gemcitabine: an active chemotherapeutic agent for angiosarcoma. Proc Am Soc Clin Oncol 2002, 21. abstr 2931.
65. Skubitz KM, Haddad PA Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma. Cancer 2005, 104:361-366.
66. Verweij J, Lee SM, Ruka W, et al. Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the european organization for research and treatment of cancer soft tissue and bone sarcoma group. J Clin Oncol 2000, 18:2081-2086.
67. Fata F, O'Reilly E, Ilson D, et al. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer 1999, 86:2034-2037.
68. Nagano T, Yamada Y, Ikeda T, Kanki H, Kamo T, Nishigori C Docetaxel: a therapeutic option in the treatment of cutaneous angiosarcoma: report of 9 patients. Cancer 2007, 110:648-651.
69. Penel N, Bui BN, Bay JO, et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol 2008, 26:5269-5274.
70. Koontz BF, Miles EF, Rubio MA, et al. Preoperative radiotherapy and bevacizumab for angiosarcoma of the head and neck: two case studies. Head Neck 2008, 30:262-266.
71. Verschraegen CF, Quinn R, Rabinowitz I, Arias-Pulido H, Muller C Phase I/II study of docetaxel (D), gemcitabine (G), and bevacizumab (B) in patients (pts) with advanced or recurrent soft tissue sarcoma (STS). Proc Am Soc Clin Oncol 2008, 26. abstr 10534.
72. Agulnik M, Okuno SH, Von Mehren M, et al. An open-label multicenter phase II study of bevacizumab for the treatment of angiosarcoma. Proc Am Soc Clin Oncol 2009, 27. abstr 10522.
73. Maki RG, D'Adamo DR, Keohan ML, et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 2009, 27:3133-3140.
74. Ryan CW, von Mehren M, et al. Phase II intergroup study of sorafenib (S) in advanced soft tissue sarcomas (STS): SWOG 0505. Proc Am Soc Clin Oncol 2008, 26:10532.
75. George S, Merriam P, Maki RG, et al. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol 2009, 27:3154-3160.
76. Raina V, Sengar M, Shukla NK, et al. Complete response from thalidomide in angiosarcoma after treatment of breast cancer. J Clin Oncol 2007, 25:900-901.
77. Taylor KL, Oates RK, Grane R, Leaman DW, Borden EC, Lindner DJ IFN-alpha1,8 inhibits tumor-induced angiogenesis in murine angiosarcomas. J Interferon Cytokine Res 2006, 26:353-361.
78. Burns BT, Blakey SA, Harris WB Complete response of metastatic angiosarcoma to liposomal doxorubicin and interferon-2a. Proc Am Soc Clin Oncol 2002, 21. 2939 (abstr).
79. Ohguri T, Imada H, Nomoto S, et al. Angiosarcoma of the scalp treated with curative radiotherapy plus recombinant interleukin-2 immunotherapy. Int J Radiat Oncol Biol Phys 2005, 61:1446-1453.